1-7 of 7
Claes Wahlestedt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Terra L. Lasho, Jenna A. Fernandez, Jeong-Heon Lee, Linh D. Pham, Huihuang Yan, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Naseema Gangat, Joseph Collard, Claes Wahlestedt, Mrinal M. Patnaik, Moritz Binder
Journal: Blood
Blood (2024) 144 (Supplement 1): 3197.
https://doi.org/10.1182/blood-2024-204070
Published: 2024
Journal Articles

Targeting Oncogenic Enhancers in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Terra L Lasho, Christy M Finke, Jenna A. Fernandez, Christopher T. Schmitz, Karl J. Clark, Claes Wahlestedt, Judy Chiao, Abhishek A Mangaonkar, Mrinal M. Patnaik, Moritz Binder
Journal: Blood
Blood (2023) 142 (Supplement 1): 1413.
https://doi.org/10.1182/blood-2023-178083
Published: 2023
Journal Articles

Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies

Hui Yang, Stefan Kurtenbach, Ying Guo, Ines Lohse, Michael A. Durante, Jianping Li, Zhaomin Li, Hassan Al-Ali, Lingxiao Li, Zizhen Chen, Matthew G. Field, Peng Zhang, Shi Chen, Shohei Yamamoto, Zhuo Li, Yuan Zhou, Stephen D. Nimer, J. William Harbour, Claes Wahlestedt, Mingjiang Xu, Feng-Chun Yang
Journal: Blood
Blood (2018) 131 (3): 328–341.
https://doi.org/10.1182/blood-2017-06-789669
Published: 2018
Includes: Supplemental data
Journal Articles

Gain-of-Function of ASXL1 Truncating Protein in the Pathogenesis of Myeloid Malignancies

Hui Yang, PhD, Stefan Kurtenbach, PhD, Ying Guo, MD PhD, Ines Lohse, PhD, Michael Durante, PhD candidate, Peng Zhang, PhD, Yuan Zhou, PhD, William Harbour, MDPhD, Claes Wahlestedt, Mingjiang Xu, MDPhD, Feng-Chun Yang, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 564.
https://doi.org/10.1182/blood.V130.Suppl_1.564.564
Published: 2017
Journal Articles

A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy

Diana Azzam, PhD, Claude-Henry Volmar, PhD, Al-Ali Hassan, PhD, Aymee Perez, PhD, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Francisco Vega, MD PhD, Arthur Zelent, PhD, Christopher R. Cogle, MD, Claes Wahlestedt, PhD, Ronan T. Swords, MDPhDFRCPI FRCPath
Journal: Blood
Blood (2015) 126 (23): 1352.
https://doi.org/10.1182/blood.V126.23.1352.1352
Published: 2015
Journal Articles

The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro

Ronan T. Swords, MDPhDFRCPI FRCPath, Shaun Brothers, PhD, Nagi Ayad, PhD, Aymee Perez, PhD, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Ana Rodriguez, Shawn Johnstone, PhD, Jeffrey Albert, Joseph Collard, Arthur Zelent, PhD, Claes Wahlestedt, PhD
Journal: Blood
Blood (2015) 126 (23): 2552.
https://doi.org/10.1182/blood.V126.23.2552.2552
Published: 2015
Journal Articles

Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression

Olof Gidlöf, Marcel van der Brug, Jenny Öhman, Patrik Gilje, Björn Olde, Claes Wahlestedt, David Erlinge
Journal: Blood
Blood (2013) 121 (19): 3908–3917.
https://doi.org/10.1182/blood-2012-10-461798
Published: 2013
Includes: Supplemental data